Episode

GLP-1s and Cancer Part 4 - Three Studies

Podcast
Weight and Healthcare
Published
Jun 24, 2026
Duration seconds
962
Processing state
not_requested
Canonical source
https://weightandhealthcare.substack.com/p/glp-1s-and-cancer-part-4-three-studies
Audio
https://api.substack.com/feed/podcast/202415105/2d9bb02126b8fa2a2e3f608f06dd66cb.mp3
JSON
/v1/public/podcasts/weight-and-healthcare-6448206/episodes/glp-1s-and-cancer-part-4-three-studies
Markdown
/podcast/weight-and-healthcare-6448206/glp-1s-and-cancer-part-4-three-studies.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/weight-and-healthcare-6448206/episodes/glp-1s-and-cancer-part-4-three-studies/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/weight-and-healthcare-6448206/glp-1s-and-cancer-part-4-three-studies.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In Part 1 we talked about the basics of the studies around GLP-1s and cancer. In part 2 we looked at a study of relatively early data around breast cancer. In part 3 we began discussing a Guardian article that made broad, unsubstantiated claims about these drugs and cancer. Today, in the final part of this series, we’ll take a look at the three studies the Guardian author quotes. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe